跳转到内容

坎妥珠单抗

维基百科,自由的百科全书

坎妥珠单抗INN:cantuzumab),也称huC242,是一种单克隆抗体,设计用于治疗癌症。它结合CanAg抗原。[1]

它通常与几种细胞毒性剂之一连接,产生抗体药物偶联物英语Antibody–drug conjugate

靶向CanAg

[编辑]

"HuC242与肿瘤相关碳水化合物抗原CanAg(MUC1的一种新型糖型)的胞外结构域结合。CanAg在大多数胰腺癌胆道癌结直肠癌中强烈表达。它还在相当大比例的胃癌(55%)、子宫癌(45%)、非小细胞肺癌(40%)和膀胱癌(40%)中表达。"[2]

参考资料

[编辑]
  1. ^ Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008, 62 (5): 911–9. PMID 18301896. S2CID 5829870. doi:10.1007/s00280-007-0672-8. 
  2. ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004. [2024-03-06]. (原始内容存档于2016-01-19).